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Abstract
Background: Human papillomavirus (HPV) prevalence in head and neck squamous cell carcinomas (HNSCC)
diverges geographically. The reliability of using p16INK4a expression as a marker of viral infection is controversial in
HNSCC. We evaluated HPV types and HPV-16 variants prevalence, and p16INK4a expression in HNSCC specimens
provided by two different Institutions in São Paulo.
Methods: HPV DNA from formalin-fixed specimens was accessed by Inno-LiPA, HPV-16 variants by PCR-sequencing,
and p16INK4a protein levels by immunohistochemistry.
Results: Overall, HPV DNA was detected among 19.4 % of the specimens (36/186). Viral prevalence was higher in
the oral cavity (25.0 %, 23/92) then in other anatomical sites (oropharynx 14,3 %, larynx 13.7 %) when samples from
both Institutions were analyzed together. HPV prevalence was also higher in the oral cavity when samples from
both Institutions were analyzed separately. HPV-16 was the most prevalent type identified in 69.5 % of the HPV
positive smaples and specimens were assigned into Asian-American (57.2 %) or European (42.8 %) phylogenetic
branches. High expression of p16INK4a was more common among HPV positive tumors.
Conclusion: Our results support a role for HPV-16 in a subset of HNSCC.
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Background
Worldwide head and neck squamous cell carcinoma
(HNSCC) is the sixth most common type of cancer with an
estimated annual incidence of approximately 600,000 cases
[1]. HNSCC comprises squamous cell carcinomas (SCC) of
the oral cavity, oropharynx, larynx and hypopharynx. In
Brazil, head and neck cancer is the fourth and seventh most
incident tumor among man and women, respectively [2].
Although alcohol and tobacco consumption is the
leading predisposing risk factor for HNSCC develop-
ment [3], there are epidemiological evidences that
human papillomavirus (HPV) infection further plays an
etiological role. In fact, since 2009, the International
Agency for Research on Cancer recognizes HPV-16 as an
independent causal agent of oropharyngeal SCC, while the
carcinogenic effect upon the oral cavity and the larynx is
still a matter of debate [4]. HPV prevalence in HNSCC
ranges from 10 % to 90 % dependent of the geographical
region and the anatomical site of the tumor [5]. HPV-
related and unrelated HNSCC diverge considerably at the
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genetic, molecular, epidemiological, and clinical level [6].
HPV-positive HNSCC are more common among young
adults and non-smokers, and these individuals respond
better to treatment and have better survival than their
HPV-negative counterparts [7].
HPV-16 intratype nucleotide heterogeneity has been
extensively studied [8]. Based on differences in identity
of less than 2 % within the L1 gene, HPV-16 molecular
variants are clustered in five branches of phylogenetic
and geographical relatedness: European (E), Asian-
American (AA), Asian (As), African-1 (Af-1) and
African-2 (Af-2) [9, 10]. The association of HPV-16 non-
European variants with increased risk of developing
cervical intraepithelial neoplasia (CIN) was observed in
several studies in Brazil and the United States [11–13].
The detection of HPV DNA in HNSCC is not a suffi-
cient proof for causal viral association. High-risk HPV
E7 inactivates the retinoblastoma protein, thus promot-
ing p16INK4 overexpression. In the cervix, p16INK4a up-
regulation is being used as an indirect measure of
oncogenically active HPV infection [14]. Although HPV
DNA detection associated to high levels of p16INK4a has
also been used as surrogate marker of biologically rele-
vant viral infections in the oropharynx [15], for other
head and neck subsites data is still inconsistent. It is cru-
cial to precisely identify HPV-driven HNSCC in each
population in order to improve clinical management of
this disease, and to evaluate the potential benefits of the
prophylactic vaccines available. Our aim was to analyze
the prevalence of HPV types and HPV-16 variants in
HNSCC from different anatomical sites of individuals
treated at two Institutions in the city of São Paulo, and
further evaluate p16INK4a protein levels in these samples.
Methods
Clinical samples
Inclusion criteria consisted of histological confirmation
of HNSCC, information about the year of diagnosis and
no treatment prior to surgical procedure. Formalin-fixed
Paraffin Embedded (FFPE) tumor specimens from 96
HNSCC patients diagnosed between 1991 and 2010 were
retrieved from the pathology archives of the Santa Casa
de Sao Paulo, School of Medicine (FCMSCSP). Further,
109 FFPE HNSCC specimens from patients treated at
the Cancer Institute of São Paulo (ICESP) from 2009 to
2012 were included in this study. Samples were selected
from the pathology services of both institutions follow-
ing a chronological sequence, availability and quality of
specimen (for molecular analyses). All sections were
reviewed by a pathologist of each participant Institution.
Based on anatomical subsite localization of the tumor,
specimens were categorized as oral cavity (oral tongue,
gum, mouth, floor of mouth, lips), oropharynx (base of
tongue, tonsil, oropharynx), and larynx, according to
The International Classification of Diseases criteria of
the World Health Organization. The ethics committees
of both institutions approved all study procedures.
DNA Extraction and HPV detection
About ten 6 μm paraffin sections were obtained; the first
and last sections were submitted to histological analysis,
while the remaining was submitted to DNA isolation.
After removing paraffin with xylene, tissues were
digested with proteinase K 1 mg/mL-SDS 0.1 % for 24 h.
DNA was obtained by organic extraction: after addition
of Phenol/Chloroform/Isoamyl Alcohol at 25:24:1
followed by vigorous homogenization and centrifugation,
DNA precipation was conducted with ethanol 100 %.
The DNA pellet was dried and was dissolved in 100 μL
of TE. DNA concentration was determined with a Nano-
drop 2000 spectrophotometer (Thermo Scientific, MA,
USA). Samples were diluted to 50 ng/uL and 2 μl were
used in each PCR. DNA quality was assessed by amplifi-
cation of a 110 bp fragment of the human β-globin gene
using PCO3/PCO4 primers followed by analysis in 8 %
acrylamide gel electrophoresis [16]. The Inno-LiPA HPV
Genotyping kit (Innogenetics, Gent, Belgium) was used
for HPV DNA detection and genotyping as described
[17]. This kit identifies 28 different HPV types by reverse
blot hybridization: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40,
43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 70, 71,
73, 74, 82.
HPV-16 variant characterization
A 193 bp segment of the LCR (nt 7744–33) (Forward
CTAACCTAATTGCATATTTGG; Reverse ACGCCCT
TAGTTTTATACATG) and/or a 108 bp fragment of the
E6 gene (nt 266–374) (Forward AGAGATGGGAATC
CATATGC; Reverse: GCTGTTCTAATGTTGTTCCA
TAC) were amplified using AmpliTaq Gold polymerase
(Perkin-Elmer, CA, USA). PCR products were cloned
with TOPO TA Cloning® kit for Sequencing (Invitrogen,
CA, USA). Sequencing was conducted in a PRISM® 3100
Genetic Analyser (AB Applied Biosystems, CA, USA)
using the BigDye Terminator v3.1 Cycle Sequencing kit
(AB Applied Biosystems, CA, USA). Sequences align-
ment was achieved using Bioedit 7.2.5, and HPV-16 vari-
ants were defined as previously described [8, 10].
P16INK4a expression
Immunohistochemistry for p16 INK4a was performed
using the CINtec® P16INK4a Histology Detection kit
(Roche Diagnostics GmbH, Mannheim, Germany) in a
Ventana Benchmark GX equipment (Ventana Medical
Systems, Arizona, USA) according to the manufacturer's
instructions. Staining of the samples from both institu-
tions (FCMSCSP and ICESP) were analyzed by the same
pathologist at ICESP (S.F.F). Expression of p16INK4a was
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scored as high (≥75 % of cells stained), low (<75 % of
cells stained) or negative (no staining). Diverse studies
use this scoring system for defining p16INK4a as positive
in oropharyngeal SCC staining [18].
Statistical analysis
Qualitative data were expressed as absolute numbers and
relative rates with 95 % confidence interval (95 % CI), and
quantitative data as means, medians and range. The Chi-
square test was used to compare phenomena between
qualitative variables. For all analysis the probability of a
making an α or type I error was equal to or less than 5 %
(P ≤ 0.05) and SPSS® version 17.0 (SPSS® Inc; Illinois, USA)
was used.
Results
All samples that were negative for human β-globin gene
amplification were excluded from the study (n = 17);
remaining 94 patients from each institution (FCMSCSP
and ICESP). The median age of patients from FCMSCSP
was 58 years, ranging from 39 to 87 years, and most in-
dividuals were male (86 %). Among specimens from
ICESP, median age was 61.5 years with a range of 43 to
91 years (Table 1).
Concerning samples obtained from FCMSCSP, most tu-
mors were from the larynx (n = 59, 62.8 %), followed by
the oral cavity (n = 22, 23.4 %) and the oropharynx (n = 11,
11.7 %). For two samples (2.1 %) the anatomic site could
not be defined due to the extension of the tumor, and both
specimens were also excluded from analysis. Most cases
from ICESP were derived from the oral cavity (n = 70,
74.5 %), followed by the oropharynx (n = 17, 18.0 %) and
the larynx (n = 7, 7.5 %).
The presence of HPV DNA was investigated in all 186
cases of HNSCC (92 from FCMSCSP and 94 from
ICESP). When the two cohorts were analyzed together,
overall HPV DNA prevalence was 19.4 % (36/186); HPV
prevalence was higher in the oral cavity (25.0 %, 23/92),
and similar viral DNA rates were observed in the
oropharynx (14.3 %, 4/28) and the larynx (13.7 %, 9/66).
HPV prevalence was also the highest in the oral cavity
when samples from both institutions were analyzed
separately: 18.2 % and 27.2 % of the samples from
FCMSCSP and ICESP were PCR positive, respectively
(Fig. 1). While among samples from FCMSCSP viral
prevalence was higher in larynx as compared to the oro-
pharynx, the opposite was observed in ICESP specimens.
Nevertheless, none of the differences observed are statis-
tically significant (P > 0.05). For both series of cases,
HPV-16 was the most commonly detected viral type,
identified in 69.5 % (25/36) of the HPV positive speci-
mens (Table 2). Co-infections by HPV-16 and HPV-18
were detected in two oral cavity samples from ICESP.
We initially thought to characterize HPV-16 molecular
variants based in the nucleotide sequence pattern of a
fragment of the E6 gene. However, we were unable to
amplify this viral segment in six samples. For this reason,
we further performed a PCR using primers able to amp-
lify a segment of the HPV-16 LCR. Even though, we had
no success in the amplification of four specimens. Over-
all, we detected European and Asian-American HPV-16
variants in 12 (57.2 %) and 9 (42.8 %) of the specimens,
respectively (Table 3).
It was possible to evaluate p16INK4a expression by im-
munohistochemistry in 94 and 87 specimens from
FCMSCSP and ICESP, respectively. Table 4 shows the
association of HPV positivity and p16INK4a expression in
the different HNSCC tumor sites of samples obtained
from both institutions. We observed that independently
of the anatomical site of the tumor, p16INK4a high ex-
pression (>75 % of cells stained) was more common
among HPV positive specimens.
Discussion
Since the early 1980s morphological and immunohisto-
chemical evidence points towards the involvement of
HPV in oral SCC [19]. Furthermore, risk factors for
HNSCC are remarkably comparable to those of cervical
cancer, comprising multiple sexual partners, younger age
at first sexual intercourse and oral sex practice [20, 21].
Actually, over the last decade it became clear that HPV-
16 is etiologically linked to a defined subset of HNSCC,
mainly in the oropharynx, and more specifically in the
tonsils [22]. An etiologic link between HPV and non-
oropharyngeal tumors is less firmly established [23, 24].
Reported detection rates of HPV DNA in HNSCC
worldwide vary considerably, ranging from 0 % to 100 %
in the oropharynx [25]. Nevertheless, HPV is recognized
by now as the major cause of oropharyngeal cancer in
developed countries, and HPV-16 detection is associated
to the rapid rise in the incidence of this neoplasia over
the last decade particularly in the USA, Sweden, and
Australia, where it causes more than 50 % of cases [26, 27].
Table 1 Age and gender of HNSCC individuals from ICESP and
FCMSCSP
Gender Age (years)
n Mean Median Range
FCMSCSP Overall 94 59.9 58.0 39-87
Female 13 64.5 63.0 45-87
Malea 81 59.1 57.5 39-85
ICESP Overall 94 63.4 61.5 43-91
Female 28 68.6 68.0 43-91
Male 66 61.2 59.0 44-86
aFor 5 men enrolled at FCMSCSP no age data available. FCMSCSP-Santa Casa
de Sao Paulo, School of Medicine; ICESP-Cancer Institute of São Paulo
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Among the HNSCC samples analyzed in our study, overall
HPV prevalence was 19.4 %, being highest in the oral cav-
ity as compared to the other anatomical sites. Our results
are consistent with another studies conducted in São Paulo
and Rio de Janeiro in which HPV prevalence observed was
19.2 % (22/114) and 15.5 % (11/71) in oral SCC, respect-
ively [28, 29], but is otherwise much higher than described
in another study involving 132 oral tumor samples from
four countries in Latin America including Brazil (HPV
prevalence was 0.0 %) [30]. When restricting the compari-
son solely to laryngeal SCC, we detected HPV DNA
in ~14.0 % of the samples from both institutions, similar
to previously reported in a study that gathered samples
from 4 Brazilian cities [31]. We have also found higher
HPV DNA prevalence in oropharyngeal cancers as previ-
ously reported on tumors from Brazil [30, 31]. Interest-
ingly, we found differences in oropharyngeal HPV
prevalence between the two groups of samples analyzed
by us (9.0 % in FCMSCSP and 17.7 % in ICESP). Never-
theless, for all anatomical sites our study has detected
lower HPV DNA prevalence when compared to studies
conducted in the USA and Europe [5, 26, 32]. Divergence
in HPV DNA rates observed could be attributed not only
to differences in the methodologies used for HPV detec-
tion in the different studies, but also to the characteristics
of the individuals under study, including sexual practices,
economic and social status. Unfortunately, the lack of
sociodemographic and sexual behavior information of
the individuals evaluated by us hampers any add-
itional analysis.
Consistent with all studies conducted worldwide HPV-
16 was the most prevalent viral type detected independ-
ently of the HNSCC anatomical subsite, and was identified
in 69.5 % (25/36) of the HPV positive tumors. We and
others have reported that in the uterine cervix non-
European variants are linked to a higher oncogenic poten-
tial [33, 34], and to increased risk of invasive cancer as
compared to European isolates [11, 12]. Concerning HPV-
16 intratypic analysis in HNSCC, there is still limited data
available. Gillison [22] examined HPV-16 sequence vari-
ability in 52 HNSCC in the USA and detected a predom-
inance of European variants (75 %), while Asiatic (17 %),
Fig. 1 Overall HPV DNA prevalence by anatomical subsite and sample origin. Prevalence (%) and 95 % CI are indicated. FCMSCSP-Santa Casa de
Sao Paulo, School of Medicine; ICESP-Cancer Institute of São Paulo
Table 2 HPV type specific prevalence by anatomical subsite and sample origin
HPV neg HPV pos HPV6 HPV11 HPV16 HPV18 HPV35 HPV52 HPV58 HPV74
FCMSCSP
oral cavity 18 4 2 2
oropharynx 10 1 1
larynx 51 8a 6 1
ICESP
oral cavityb 51 19 1 14 4 1 1
oropharynx 14 3 3
larynx 6 1 1
aOne of the samples was HPV positive but viral type was not discriminated using Inno-Lipa
bTwo cases of multiple infection with HPV-16 and HPV-18
FCMSCSP-Santa Casa de Sao Paulo, School of Medicine; ICESP-Cancer Institute of São Paulo. Neg-negative. Pos-positive
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North-American (4 %) and African (4 %) variants were
less represented. Furthermore, as previously reported for
the uterine cervix, in studies conducted in Europe, >90 %
of the HPV-16 variants detected in HNSCC belongs to the
European branch [35, 36], with the exception of a study
from Italy in which about 20 % of the HPV-16 positive
cases consisted of African variants [37]. To our knowledge
this is the first report concerning description of HPV-16
variability in head and neck tumor specimens in Brazil.
Among the HNSCC samples that we were able to
characterize the HPV-16 variant, we observe overall slight
predominance of European variants followed by Asian-
American isolates, comparable to our report on normal
cervical samples [11]. In this way it seems that variant dis-
tribution reported in HNSCC merely reflects the overall
frequency of circulating variants in the populations stud-
ied and correlates with the intrinsic admixture level of
each population similar to previously reported for the
cervical region [38]. It is noteworthy, that all HPV-16
oropharyngeal SCC samples analyzed by us comprise
Asian-American variants. Still, the very limited number of
samples analyzed precludes further conclusions. Accord-
ingly, natural history studies of HPV in head and neck
subsites are crucial to better evaluate the clinical relevance
of HPV-16 heterogeneity on viral infection persistence
and HNSCC development, predominantly in oropharyn-
geal SCC where it plays a casual role.
Only the detection of HPV DNA in HNSCC biopsies
is not enough evidence of tumor causation and other pa-
rameters should be analyzed to prove the pathogenic
role of viral infection. Even though overexpression of
p16INK4a may also derive from non-viral alterations [39],
it has been proven efficient as a surrogate marker of
HPV activity in cervical samples [40]. The use of this
marker to clinically detect an oncogenically active HPV
infection in oropharyngeal SCC has also been described
[41]; however, in oral SCC, this correlation is still con-
troversial [42]. We observed that p16INK4a high expres-
sion (>75 % cells stained) was more commonly observed
in HPV positive tumors, especially among oropharyngeal
samples for which 75 % of HPV positive samples overex-
pressed this protein.
Conclusions
In summary, we observe that in our population overall
HPV prevalence is lower than reported in developed
countries, even though HPV-16 was the most prevalent
viral type as observed in all studies conducted world-
wide. HPV-16 variant distribution detected in our sam-
ples seemed to replicate data of the uterine cervix in our
population. However, the role of HPV-16 intratypic vari-
ability in HNSCC development deserves further analysis.
Nevertheless, the fact that HPV16 accounted for almost
all HPV positive HNSCC samples indicates that devel-
oped prophylactic vaccines for cervical cancer could also
be relevant for HNSCC prevention in our population.




HPV-16 AA/NA1 E Not typed
(n) n (%) n (%) n (%)
FCMSCSP Total 8 1 (12.5) 5 (62.5) 2 (25.0)
Oral cavity 2 0 (0) 2 (100.0) 0 (0)
Oropharynx 0 0 (0) 0 (0) 0 (0)
Larynx 6 1 (16.7) 3 (50.0) 2 (33.3)
ICESP Total 17 8 (47.1) 7 (41.2) 2 (11.7)
Oral cavity 14 5 (35.7) 7 (50.0) 2 (14.3)
Oropharynx 3 3 (100.0) 0 (0) 0 (0)
Larynx 0 0 (0) 0 (0) 0 (0)
FCMSCSP-Santa Casa de Sao Paulo, School of Medicine; ICESP-Cancer Institute
of São Paulo. AA/NA1-Asian-American/North American, E-European
Table 4 p16INK4a levels by immunohistochemistry among HPV positive and negative HNSCC
HPV DNA positive HPV DNA negative
p16 neg p16 low p16 high p16 neg p16 low p16 high
n (%) n (%) n (%) n (%) n (%) n (%)
FCMSCSP
total 14 (70.0) 3 (15.0) 3 (15.0) 49 (66.2) 22 (29.7) 3 (4.1)
oral cavity 4 (100.0) 0 (0) 0 (0) 9 (56.3) 7 (43.7) 0 (0)
oropharynx 0 (0) 0 (0) 1 (100.0) 5 (55.6) 3 (33.3) 1 (11.1)
larynx 5 (62.5) 1 (12.5) 2 (25.0) 35 (71.4) 12 (24.5) 2 (4.1)
ICESP
total 14 (66.7) 2 (9.5) 5 (23.8) 60 (91.0) 5 (7.5) 1 (1.5)
oral cavity 13 (76.4) 2 (11.8) 2 (11.8) 42 (89.3) 4 (8.5) 1 (2.2)
oropharynx 1 (33.3) 0 (0) 2 (66.7) 12 (92.3) 1 (7.7) 0 (0)
larynx 0 (0) 0 (0) 1 (100.0) 6 (100.0) 0 (0) 0 (0)
FCMSCSP-Santa Casa de Sao Paulo, School of Medicine; ICESP-Cancer Institute of São Paulo
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